Unicycive Therapeutics, Inc. (UNCY)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn more
What's happening with UNCY?
Powered by Yahoo ScoutUnicycive Therapeutics reported a narrowed Q2 lossof $0.06 per share, aided by an $8 million gainfrom warrant liability adjustments. Despite setbacks from an FDA Complete Response Letter on its lead drug, the company remains optimistic about its future as it prepares for a potential resubmission following a facility inspection.
- Previous Close
5.30 - Open
5.24 - Bid --
- Ask --
- Day's Range
5.12 - 5.24 - 52 Week Range
3.71 - 8.74 - Volume
-- - Avg. Volume
-- - Market Cap (intraday)
141.348M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Recent News
Statistics
View MoreValuation Measures
-
Market Cap
-
Enterprise Value
-
Trailing P/E
-
Forward P/E
-
PEG Ratio (5yr expected)
-
Price/Sales (ttm)
-
Price/Book (mrq)
-
Enterprise Value/Revenue
-
Enterprise Value/EBITDA
Financial Highlights
Profitability and Income Statement
-
Profit Margin
--
-
Return on Assets (ttm)
--
-
Return on Equity (ttm)
--
-
Revenue (ttm)
--
-
Net Income Avi to Common (ttm)
--
-
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
-
Total Cash (mrq)
--
-
Total Debt/Equity (mrq)
--
-
Levered Free Cash Flow (ttm)
--
Compare
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
